The former CEO of Allscripts, Glen Tullman, is back with a vengeance.
The well-respected business leader has just launched his newest venture, Livongo, at TechCrunch’s Disrupt conference.
According to published reports, the enterprise has already wrapped up a $10 million funding round from General Catalyst Partners.
Tullman, who has been working on the project since last year, is optimistic about Livongo which is described as a “consumer centric venture aimed at improving the management of chronic diseases.”
It aims to engage people with diabetes – old, young, type 1, or type 2 – in the management of their care.
The platform consists of a connected device called In Touch which will serve as both a connected glucometer and pedometer and allows for sharing of data. It is a standalone device with a touchscreen that is cellular connected. It is FDA-cleared with ongoing clinical tests. The platform also consists of a smart cloud and a virtual care team made up of certified diabetes educators, friends, and family selected by the user.
The platform uses the cellular network to keep the user in touch at all times, automatically transmitting blood glucose readings, activity information, and how you’re feeling.
Information from the connected device combines with clinical rules and information from the user’s physician in the smart cloud which creates personalized insight to improve the user’s health management which can be sent to the virtual care team.